New antiplatelet and anticoagulant drugs

Wynn, R.L.

General Dentistry 60(1): 8-11


ISSN/ISBN: 0363-6771
PMID: 22313973
Document Number: 13708
The antiplatelet drugs prasugrel (Eient) and ticagrelor (Brilinta, AstraZeneca LP) and the anticoagulant drugs dabigatran (Pradaxa, Boehringer Ingelheim Pharmaceuticals, Inc.) and rivaroxaban (Xarelto, Janssen Pharmaceuticals, Inc.) have gained FDA approval within the past two years. Prasugrel is a platelet aggregation inhibitor approved for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes who are managed with percutaneous coronary intervention. Prasugrel is an antiplatelet agent within the same class of platelet inhibitors as clopidogrel (Plavix). he oicial labeled indications are to reduce the rate of thrombotic cardiovascular events (for example, stent thrombosis) in patients with unstable angina, non-ST-segment elevation MI, or ST-elevation MI (STEMI) managed with percutaneous coronary intervention (PCI). A description of the medical use, efects on bleeding, and other dental considerations for prasugrel was published in this column in 2010. The remainder of this column will describe the other three new drugs.

Document emailed within 1 workday
Secure & encrypted payments

New antiplatelet and anticoagulant drugs